IQVIA(US:IQV)2026-02-05 15:02Financial Data and Key Metrics Changes - Full-year revenue growth of 6% and adjusted diluted earnings per share growth of 7% were reported, with free cash flow of $2.1 billion, representing about 100% of adjusted net income [5][21] - Fourth quarter revenue was $4.364 billion, up 10.3% on a reported basis and 8.1% at constant currency, with adjusted EBITDA increasing by 5% year-over-year [21][23] - Full-year revenue reached $16.31 billion, up 5.9% reported and 4.8% at constant currency [22] Business Line Data and Key Metrics Changes - Technology Analytics Solutions revenue for Q4 was $1.821 billion, up 9.8% reported and 7.1% at constant currency [21] - R&D Solutions revenue for Q4 was $2.333 billion, up 9.1% reported and 8.2% at constant currency [21] - Contract Sales and Medical Solutions (CSMS) revenue for Q4 was $210 million, increased 18.6% reported and 15.3% at constant currency [21] Market Data and Key Metrics Changes - Net bookings for R&D Solutions totaled over $2.7 billion, growing 7% year-over-year, with a net book-to-bill ratio of 1.18 [9][10] - Backlog reached a record $32.7 billion at the end of the quarter, growing 5.3% compared to the prior year [10][24] - EBP funding was strong in Q4, reaching $33 billion according to BioWorld [11] Company Strategy and Development Direction - The company is focusing on simplifying its organization to enhance collaboration and efficiency, aligning teams with the evolving operating model [15] - A strategic collaboration with Amazon Web Services was announced to accelerate digital transformation in the industry [11] - The company is investing in AI capabilities and has deployed over 150 AI agents across various use cases [38][41] Management's Comments on Operating Environment and Future Outlook - Management noted that the macroeconomic environment had stabilized somewhat, leading to improved demand indicators and increased funding [5][6] - The company expects revenue for 2026 to be between $17.15 billion and $17.35 billion, with adjusted EBITDA guidance of $3.975 billion to $4.025 billion [26][27] - Management expressed confidence in the resilience of the business and the potential for AI to enhance operations rather than disrupt them [62][64] Other Important Information - The company was recognized by Everest Group for AI leadership, being the only clinical research organization to receive the top ranking for generative AI leadership in life sciences [12] - The CFO, Ron Bruehlman, is transitioning to a senior advisory role after this earnings call [17][18] Q&A Session Summary Question: Concerns about AI disrupting established businesses - Management clarified that AI is viewed as an opportunity rather than a challenge, emphasizing the company's proprietary data and domain expertise as key differentiators [32][34][41] Question: Value and driver of the Cedar Gate acquisition - The acquisition is expected to enhance patient outcomes and provide analytics to payers, with projected revenue of approximately $125 million in 2024 [46][48] Question: Impact of AI on trial efficiency and demand for services - Management indicated that large pharma's use of AI for trial efficiency does not negatively impact demand for their services, and they expect to continue growing and gaining market share [70][72] Question: Margin trajectory and productivity sharing with clients - Management acknowledged that while margins were slightly down, productivity gains are shared with clients, and pass-through growth was a significant driver of gross margin [76][84]